{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 52,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Slide 20 of a presentation; includes technical definitions and study references in the footer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/19",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.033,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "Data cut-off: January 27, 2023. 1. Wu et al. N Engl J Med 2020;383:1711-1723; 2. Herbst et al. J Clin Oncol 2023; 41: 1830-1840. DFS = disease-free survival; EGFRm = epidermal growth factor receptor-mutated; NSCLC = non-small cell lung cancer; CNS = central nervous system; OS = overall survival; HR = hazard ratio.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd7d0bca-cdd0-40d0-a15b-564502abb893",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.058,
        "y": 0.75
      },
      "kind": "list",
      "text": "ADAURA is the first global Phase III study to demonstrate statistically significant and clinically meaningful OS benefit with targeted treatment in this patient population, reinforcing adjuvant Tagrisso as the standard of care for patients with resected EGFRm stage IB–IIIA NSCLC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "038f0b3f-4ac7-403f-9a9c-3415db5fcfba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.058,
        "y": 0.225
      },
      "kind": "list",
      "text": "In the ADAURA primary analysis, adjuvant Tagrisso demonstrated a statistically significant and clinically meaningful DFS benefit vs placebo in resected EGFRm stage IB–IIIA NSCLC, along with improved CNS DFS and a tolerable safety profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "063c515d-e000-4328-a858-dd768f79bcde",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.058,
        "y": 0.64
      },
      "kind": "list",
      "text": "OS benefit with adjuvant Tagrisso vs placebo was generally consistent across subgroups, including by disease stage (IB / II / IIIA) and prior adjuvant chemotherapy use (yes / no)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36b847b2-6759-4fab-88f4-9b4f305c1d9e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.058,
        "y": 0.38
      },
      "kind": "list",
      "text": "DFS benefit in ADAURA has translated into a statistically significant OS benefit with adjuvant Tagrisso vs placebo. Primary (stage II–IIIA) population, OS HR 0.49; 95.03% CI 0.33, 0.73; p=0.0004. Overall (stage IB–IIIA) population, OS HR 0.49; 95.03% CI 0.34, 0.70; p<0.0001",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b95eb8e2-b390-48d6-a4ad-460bba5b60a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.23,
        "x": 0.033,
        "y": 0.065
      },
      "kind": "title",
      "text": "Conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97e779da-3e49-496b-9c45-b41da75eec09",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "80d84c18-016b-4656-a67a-9539907e3bfa",
      "evidence": "The slide contains a list of bullet points summarizing key findings.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 15,
      "beatId": "ba7e7aa9-525b-4e2a-a4f1-214ecf8f098d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 15,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "b41eaf1b-437d-4b91-9988-0e6fb0f284a8",
      "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology",
      "position": 1,
      "objective": "What are the benefits of AstraZeneca's pipeline?",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}